News
Novo Nordisk Weaves Itself Into Seattle Biotech, With Diabetes R&D
Posted by heather on July 6, 2012
From Xconomy
By Luke Timmerman
Novo Nordisk has added another 20 people to its Seattle office as it ramps up efforts to fill the gap between federal grant funding and venture capital for promising diabetes R&D projects, welcome news for the 25.8 million Americans living with diabetes and the 79 million people with prediabetes.
Read the full article on Xconomy.com.



